MaxCyte, Inc. Director Dealings and Issue of Equity (2766T)
July 16 2020 - 1:04PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 2766T
MaxCyte, Inc.
16 July 2020
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings and Issue of Equity
Gaithersburg, Maryland - 16 July 2020: MaxCyte (LSE: MXCT,
MXCS), the global cell-based medicines and life sciences company,
announces that Doug Doerfler, Chief Executive Officer and Founder
of the Company and Ron Holtz, Chief Financial Officer, have
exercised options over 575,000 shares of common stock of $0.01 of
the Company ("Common Stock") ("Exercise") in aggregate. The 575,000
new shares of Common Stock issued pursuant to the Exercise ("New
Common Stock") have today been sold by Doug Doerfler and Ron Holtz
at a price of 220 pence per Common Stock ("Sale"). The sold shares
represent approximately 11.0 % and 11.2% of Mr. Doerfler's and Mr.
Holtz's total equity and option holdings in the Company's equity,
respectively. This share sale is the first sale of any of Mr.
Doerfler's or Mr. Holtz's equity in the Company since it's founding
in 1999 and Mr. Doerfler and Mr. Holtz have no current intention of
making further sales of MaxCyte shares.
Following the Exercise and Sale, Mr Doerfler's holding of Common
Stock remains unchanged at a total of 433,197 Common Stock and Mr
Holtz's holding of Common Stock remains unchanged at a total of
150,251 Common Stock, representing 0.57% and 0.20%, respectively,
of the enlarged issued share capital of the Company and following
the Exercise, Mr. Doerfler and Mr. Holtz hold a further 2,813,480
and 1,239,892 options over Common Stock.
Total voting rights
Application will be made for admission of the 575,000 New Common
Stock to trading on AIM, which is anticipated to occur at 8:00am on
23 July 2020 ("Admission"). The New Common Stock will rank pari
passu with the existing shares of common stock of the Company and
will trade in the unrestricted line of Common Stock trading under
the symbol MXCT. The total issued stock capital of the Company
following the above will be 77,160,006 shares of common stock.
Shareholders in the Company may use this figure as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the stock capital of the Company.
The number of unrestricted shares of Common Stock trading under
the symbol 'MXCT' is 67,259,917 and the number of restricted shares
of Common Stock trading under the symbol 'MXCL' is 9,900,089.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Doug Doerfler
=============================== ===========================================
2 Reason for the notification
============================================================================
a) Position/status Chief Executive Officer
=============================== ===========================================
b) Initial notification/Amendment Initial notification
=============================== ===========================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
============================================================================
a) Name MaxCyte, Inc.
=============================== ===========================================
b) LEI 54930053YHXULRFCU991
=============================== ===========================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
============================================================================
a) Description of Exercise of options and Sale of Common
the financial Stock
instrument, type
of instrument
=============================== ===========================================
b) Identification US57777K1060
Code
=============================== ===========================================
c) Nature of the Exercise of options and Sale of Common
transaction Stock by PDMR
=============================== ===========================================
d) Price(s) and volume(s) Price(s) Volume(s)
=============================== ================ =========================
N/A 400,000 (option exercise)
220 pence 400,000 (sale of common
stock)
=============================== ================ =========================
e) Aggregated information N/A
- Aggregated volume N/A
- Price N/A
=============================== ===========================================
f) Date of the transaction 16 July 2020
=============================== ===========================================
g) Place of the transaction London Stock Exchange, AIM Market (XLON)
=============================== ===========================================
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Ron Holtz
=============================== ===========================================
2 Reason for the notification
============================================================================
a) Position/status Chief Financial Officer
=============================== ===========================================
b) Initial notification/Amendment Initial notification
=============================== ===========================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
============================================================================
a) Name MaxCyte, Inc.
=============================== ===========================================
b) LEI 54930053YHXULRFCU991
=============================== ===========================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
============================================================================
a) Description of Exercise of options and Sale of Common
the financial Stock
instrument, type
of instrument
=============================== ===========================================
b) Identification US57777K1060
Code
=============================== ===========================================
c) Nature of the Exercise of options and Sale of Common
transaction Stock by PDMR
=============================== ===========================================
d) Price(s) and volume(s) Price(s) Volume(s)
=============================== ================ =========================
N/A 175,000 (option exercise)
220 pence 175,000 (sale of common
stock)
=============================== ================ =========================
e) Aggregated information N/A
- Aggregated volume N/A
- Price N/A
=============================== ===========================================
f) Date of the transaction 16 July 2020
=============================== ===========================================
g) Place of the transaction London Stock Exchange, AIM Market (XLON)
=============================== ===========================================
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company. As the inventors of the premier cell-engineering
enabling technology, the Company helps bring the promise of
next-generation cell and gene-editing therapies to life. The
Company's technology is currently being deployed by leading drug
developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for
more than 120 cell therapy programmes, with more than 90 licensed
for clinical use, and the Company has now entered into eleven
clinical/commercial license partnerships with leading cell therapy
and gene editing developers. MaxCyte was founded in 1998, is listed
on the London Stock Exchange (AIM:MXCT, MXCL) and is
headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com .
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCRFMRTMTMBBTM
(END) Dow Jones Newswires
July 16, 2020 13:04 ET (17:04 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Dec 2023 to Dec 2024
